Document is current

Article History

Received: 19 December 2020

Accepted: 22 April 2021

First Online: 2 June 2021

Declarations

:

: This study received ethics approval by the Goethe-University Frankfurt (reference 324/18), and all participants provided informed consent.

: Not applicable.

: JPZ reports speakers’ honoraria and travel grants from EISAI and Desitin Arzneimittel. FR reports personal fees from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Novartis, Medtronic, Sandoz, Shire, and UCB, and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the European Union. MS reports personal fees from Novartis and GW Pharmaceuticals companies. GK reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, UCB, Novartis, Takeda, and Zogenix. TM reports personal fees and grants from Arvelle Therapeutics, Eisai, GW Pharmaceuticals companies, UCB, and Zogenix. AB reports personal fees from Desitin Arzneimittel GmbH, Eisai GmbH, Eisai GmbH, Shire GmbH, UCB Pharma GmbH, and ViroPharma GmbH. KMK reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai, and GW Pharmaceuticals, grants from the federal state Hessen through the LOEWE program, and from the Canadian Institutes of Health Research. SM reports grants from Novartis, UCB, Shire, Deutsche Forschungsgemeinschaft and Epilepsiestiftung Dr. Wolf. FvP reports personal fees and grants from Bial, Desitin Arzneimittel, Eisai, GW Pharmaceutical companies, Arvelle Therapeutics, and UCB Pharma. SS-B reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UCB, and Zogenix. AS reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, LivaNova, Marinus Pharma, Medtronic, UCB, and Zogenix. None of the other authors reported any related conflicts of interest.